The natural history of multiple sclerosis is highly variable. There is
substantial heterogeneity in the clinical manifestations but at this
point it is reasonable to consider all idiopathic inflammatory demyeli
nating diseases of the central nervous system as representing a spectr
um of the same disease. The short- and long-term course of multiple sc
lerosis may be determined by different biologic variables. Short-term
benefit in clinical trials should not be assumed to indicate long-term
reduction in the risk of permanent disability.